Cancer Research Cell Death Mechanisms and Cancer Therapy Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, G. L.
Right arrow Articles by Gerstenfeld, L. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, G. L.
Right arrow Articles by Gerstenfeld, L. C.
[Cancer Research 64, 4506-4513, July 1, 2004]
© 2004 American Association for Cancer Research

Regular Articles

Fidelity of Runx2 Activity in Breast Cancer Cells Is Required for the Generation of Metastases-Associated Osteolytic Disease

George L. Barnes1, Kerri E. Hebert1, Mohammad Kamal1, Amjad Javed2, Thomas A. Einhorn1, Jane B. Lian2, Gary S. Stein2 and Louis C. Gerstenfeld1

1 Department of Orthopaedic Surgery, Boston University Medical Center, Boston, and 2 Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts

The osteolytic bone destruction associated with breast cancer skeletal metastases represents a serious and incurable clinical condition. However, the molecular mechanisms regulating tumor cell expression of factors involved in the generation of osteolytic disease remain elusive. We demonstrated recently that breast cancer cells express the Runx2 transcription factor, essential for bone formation and a regulator of skeletal homeostasis. Our experimental results demonstrate that perturbation of Runx2 regulatory function in tumor cells abolishes their ability to form osteolytic lesions in vivo. In vitro, we show that breast cancer cells inhibit osteoblast differentiation while concurrently enhancing osteoclast differentiation in marrow stromal cell cultures. Disruption of Runx2 activity abrogates both of these cancer cell-mediated effects on bone cells. These results demonstrate that Runx2 expression in breast cancer cells provides a molecular phenotype that enables the interactions between tumor cells and the bone microenvironment that lead to osteolytic disease.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
C. Ge, G. Xiao, D. Jiang, Q. Yang, N. E. Hatch, H. Roca, and R. T. Franceschi
Identification and Functional Characterization of ERK/MAPK Phosphorylation Sites in the Runx2 Transcription Factor
J. Biol. Chem., November 20, 2009; 284(47): 32533 - 32543.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pratap, K. M. Imbalzano, J. M. Underwood, N. Cohet, K. Gokul, J. Akech, A. J. van Wijnen, J. L. Stein, A. N. Imbalzano, J. A. Nickerson, et al.
Ectopic Runx2 Expression in Mammary Epithelial Cells Disrupts Formation of Normal Acini Structure: Implications for Breast Cancer Progression
Cancer Res., September 1, 2009; 69(17): 6807 - 6814.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. K. Baniwal, O. Khalid, D. Sir, G. Buchanan, G. A. Coetzee, and B. Frenkel
Repression of Runx2 by Androgen Receptor (AR) in Osteoblasts and Prostate Cancer Cells: AR Binds Runx2 and Abrogates Its Recruitment to DNA
Mol. Endocrinol., August 1, 2009; 23(8): 1203 - 1214.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
O. Khalid, S. K. Baniwal, D. J. Purcell, N. Leclerc, Y. Gabet, M. R. Stallcup, G. A. Coetzee, and B. Frenkel
Modulation of Runx2 Activity by Estrogen Receptor-{alpha}: Implications for Osteoporosis and Breast Cancer
Endocrinology, December 1, 2008; 149(12): 5984 - 5995.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pratap, J. J. Wixted, T. Gaur, S. K. Zaidi, J. Dobson, K. D. Gokul, S. Hussain, A. J. van Wijnen, J. L. Stein, G. S. Stein, et al.
Runx2 Transcriptional Activation of Indian Hedgehog and a Downstream Bone Metastatic Pathway in Breast Cancer Cells
Cancer Res., October 1, 2008; 68(19): 7795 - 7802.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H.-F. Yuen, W.-K. Kwok, K.-K. Chan, C.-W. Chua, Y.-P. Chan, Y.-Y. Chu, Y.-C. Wong, X. Wang, and K.-W. Chan
TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction
Carcinogenesis, August 1, 2008; 29(8): 1509 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E.-L. Alarmo, T. Korhonen, T. Kuukasjarvi, H. Huhtala, K. Holli, and A. Kallioniemi
Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas
Ann. Onc., February 1, 2008; 19(2): 308 - 314.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Le Gall, A. Bellahcene, E. Bonnelye, J. A. Gasser, V. Castronovo, J. Green, J. Zimmermann, and P. Clezardin
A Cathepsin K Inhibitor Reduces Breast Cancer Induced Osteolysis and Skeletal Tumor Burden
Cancer Res., October 15, 2007; 67(20): 9894 - 9902.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
A. A.N. Rose, F. Pepin, C. Russo, J. E. Abou Khalil, M. Hallett, and P. M. Siegel
Osteoactivin Promotes Breast Cancer Metastasis to Bone
Mol. Cancer Res., October 1, 2007; 5(10): 1001 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. W. Young, M. Q. Hassan, X.-Q. Yang, M. Galindo, A. Javed, S. K. Zaidi, P. Furcinitti, D. Lapointe, M. Montecino, J. B. Lian, et al.
Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2
PNAS, February 27, 2007; 104(9): 3189 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Qiao, P. Shapiro, M. Fosbrink, H. Rus, R. Kumar, and A. Passaniti
Cell Cycle-dependent Phosphorylation of the RUNX2 Transcription Factor by cdc2 Regulates Endothelial Cell Proliferation
J. Biol. Chem., March 17, 2006; 281(11): 7118 - 7128.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. Pratap, A. Javed, L. R. Languino, A. J. van Wijnen, J. L. Stein, G. S. Stein, and J. B. Lian
The Runx2 Osteogenic Transcription Factor Regulates Matrix Metalloproteinase 9 in Bone Metastatic Cancer Cells and Controls Cell Invasion
Mol. Cell. Biol., October 1, 2005; 25(19): 8581 - 8591.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. K. Inman, N. Li, and P. Shore
Oct-1 Counteracts Autoinhibition of Runx2 DNA Binding To Form a Novel Runx2/Oct-1 Complex on the Promoter of the Mammary Gland-Specific Gene {beta}-casein
Mol. Cell. Biol., April 15, 2005; 25(8): 3182 - 3193.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Javed, G. L. Barnes, J. Pratap, T. Antkowiak, L. C. Gerstenfeld, A. J. van Wijnen, J. L. Stein, J. B. Lian, and G. S. Stein
Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo
PNAS, February 1, 2005; 102(5): 1454 - 1459.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.